Synthesis and structure-activity relationships of novel histamine H 1 antagonists: Indolylpiperidinyl benzoic acid derivatives

Journal of Medicinal Chemistry

Volumn 47, Issue 25, 2004, Pages 6326-6337

  Fonquerna, Silvia ^a,b   Miralpeix, Montse ^a,b,c   Pagès, Lluís ^a,b   Puig, Carles ^a,b   Cardús, Arantxa ^a,b   Antón, Francisca ^a,b   Cárdenas, Álvaro ^a,b   Vilella, Dolors ^a,b   Aparici, Mónica ^a,b   Calaf, Elena ^a,b   Prieto, José ^a,b   Gras, Jordi ^a,b   Huerta, Josep M ^a,d   Warrellow, Graham ^a,b   Beleta, Jorge ^a,b   Ryder, Hamish ^a,b  

^a Research Center ^*  (Spain)

^b Department of Medicinal Chemistry ^*  (Spain)

^c Department of Biology ^*  (Spain)

^d Drug Discovery Division

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 5 [4 (1 THIOPHEN 2 YLMETHYL 1H INDOL 3 YL)PIPERIDIN 1 YLMETHYL]BENZOIC ACID; 2 METHOXY 5 [4 [1 (2 METHOXYETHYL) 1H INDOL 3 YL]PIPERIDIN 1 YLMETHYL]BENZOIC ACID; 2 [2 [4 [1 (2 DIOXOLAN 2 YLETHYL) 1H INDOL 3 YL]PIPERIDIN 1 YL]ETHOXY]BENZOIC ACID; 2 [2 [4 [6 FLUORO 1 (2 METHOXYETHYL) 1H INDOL 3 YL]PIPERIDIN 1 YL]ETHOXY]BENZOIC ACID; 5 [4 (6 FLUORO 1 THIOPHEN 2 YLMETHYL 1H INDOL 3 YL)PIPERIDIN 1 YLMETHYL] 2 METHOXYBENZOIC ACID; BENZOIC ACID DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; INDOLYLPIPERIDINYL BENZOIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HALF LIFE TIME; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; REACTION OPTIMIZATION; SKIN PERMEABILITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 9744279706     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0498203     Document Type: Article

References (23)

1. Newacheck, P. W.; Stoddard, J. J. Prevalence and impact of multiple childhood chronic illnesses. J. Pediatr. 1984, 124, 40-48.
2. Fineman, S. M. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol. 2002, 88, 2-7.
3. Bousquet, J.; Vignola, A. M.; Campbell, A. M. Pathophysiology of allergic rhinitis. Int. Arch. Allergy Immunol. 1996, 110, 207-218.
4. Berger, W. E. Overview of allergic rhinitis. Ann. Allergy Asthma Immunol. 2003, 90, 7-12.
5. Bousquet, J.; Van Cauwenberge, P.; Khaltaev, N. Allergic rhinitis and its impact in asthma. J. Allergy Clin. Immunol. 2001, 108, S147-S334.
6. Scadding, G. K. Clinical assessment of antihistamines in rhinitis. Clin. Exp. Allergy 1999, 29, supplement 3, 77.
7. Walsh, G. M. The clinical relevance of anti-inflammatory properties of antihistamines. Allergy 2000, 55, 53-61.
8. Kay, G. G. The effects of antihistamines on cognition and performance. J. Allergy Clin. Immunol. 2000, 105, S622-S627.
9. Schultz, A.; Stuck, B. A.; Feuring, M.; Hörmann, K.; Wehling, M. Novel approaches in the treatment of allergic rhinitis. Curr. Opin. Allergy Clin. Immunol. 2003, 3, 21-27.
10. DuBuske, L. M. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin. Ther. 1999, 21, 281-295.
11. Nicolas, J. M. The metabolic profile of second-generation anti-histamines. Allergy 2000, 55, 6-52.
12. Booth, R. J.; Hodges, J. C.; Polymer-supported quenching reagents for parallel purification. J. Am. Chem. Soc. 1997, 119, 4882-4886.
13. Suto, M. J.; Gayo-Fung, L. M.; Palanki, M. S. S.; Sullivan, R. Solution-phase parallel synthesis using ion-exchange libraries. Tetrahedron 1998, 54, 4141-4150.
14. 3H-mepyramine Binding of brain membranes. J. Neurochem. 1979, 32, 1653-1663.
15. Pazos, A.; Hoyer, D.; Palacios, J. M. Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. Eur. J. Pharmacol. 1985, 106, 531-538.
16. Greengrass, P.; Bremner, R. Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 1979, 55, 323-326.
17. Martin, U.; Baggiolini, M.; Dissocation between the anti-anphylactic and the anti-histaminic actions of ketotifen. Naunyn-Schmiedeberg's Arch Pharmacol. 1981, 316, 186-189.
18. 1 receptor binding in vitro and ex vivo of nonsedating antihistamines and of norebastine, a new agent. Drug Dev. Res. 1991, 22, 165-178.
19. Llenas, J.; Gras, J.; Palacios, J. M.; Roberts, D. Comparative intravenous effects of terfenadine and ebastine on QTc prolongation in anaesthetised guinea pigs. J. Allergy Clin. Immunol. 1999, 103, S256.
20. Fujisawa Pharmaceutical Co. EP 0324431 (1989). New indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical compositions.
21. Simons, F.; Fraser, T. G.; Reggin, J. D.; Simons, K. J. Comparison of the central nervous system effect prodcued by six Hi-receptor antagonists. Clin. Exp. Allergy 1996, 26, 1092-1097.
22. Salmun, L. M.; Gates, D.; Scharf, M. Loratadine versus cetirizine: assesment of somnolence and motivation during the workday. Clin. Ther. 2000, 22, 573-582.
23. Freter, K.; Fuchs, V.; Barsumian, E.; Oliver, J. T.: 4-(Indolyl-3)-1- (benzimidazolonylalkyl)piperidines, a novel group of potential antiallergy compounds. Arneimittel-Forschung 1985, 35 (1A), 272-276.